Tagged with clinic

clinical research The general director of the National Institute for Psychiatry discusses the Institute’s commitment to translating clinical research into better care for patients, the social stigma patients with mental disorders still face in Mexico and the increasing importance of mental health on productivity and the country’s economic development. You have been…

clinical trials The global CEO of Arianne, who herself happens to be American-Algerian, outlines why, in an era of clinical research globalisation, the country has all the right fundamentals in place to establish itself as a leader in conducting clinical trials and how the Algerian genetic code is well suited for testing Western orientated pharmaceutical…

clinical trials LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth outside of Korea.   When we met you in 2008, you were positive about the growth of Korean CROs and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

partnering The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about his current operations and his vision for the future.     Can you discuss the role that KIT plays today…

clinical trials The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country.   You became president of Astellas Korea in 2011, following a long career at this affiliate. What were the biggest objectives you had when…

clinical trials The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans.   What differentiates P&K Skin from its competitors, and what are the key characteristics of the Korean market that attract foreign patients and companies? We…

hospital The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases.   As a leading expert in rheumatism, what have been some of the main developments in this particular area of study? Rheumatologic…

clinical trials The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research network. Deborah Chee, president of KoNECT, explains the organization’s ambition to become a world leader in clinical trials.   When…

Parexel Pilar Rivas, associate director of global contract research organization Parexel’s Spanish affiliate, discusses cultural differences across Spain and their impact on clinical trials, as well as the world-class infrastructure that allows CROs in Spain to perform high-quality research.   Do you feel that supporting clinical research is a priority for the…

Biotech The CEO of Venter Pharma explains the challenges of bringing a diagnostic drug to the market, and how they hope to leverage the science behind their product, LacTEST, in various new forms and indications.   Before you came on board at Venter Pharma, the research for your product LacTEST was…

university The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader for plasma derived therapies in the region, and their exciting pipeline of innovative biotech products.     How does Hemoderivados’s…